| Suppression of the FOXM1 transcriptional programme via novel small molecule inhibition MV Gormally, TS Dexheimer, G Marsico, DA Sanders, C Lowe, ... Nature communications 5 (1), 5165, 2014 | 200 | 2014 |
| Efficacy and safety of COVID-19 convalescent plasma in hospitalized patients: a randomized clinical trial MB Ortigoza, H Yoon, KS Goldfeld, AB Troxel, JP Daily, Y Wu, Y Li, D Wu, ... JAMA internal medicine 182 (2), 115-126, 2022 | 73 | 2022 |
| FOXM1 binds directly to non-consensus sequences in the human genome DA Sanders, MV Gormally, G Marsico, D Beraldi, D Tannahill, ... Genome biology 16, 1-23, 2015 | 61 | 2015 |
| Matrix screen identifies synergistic combination of PARP inhibitors and nicotinamide phosphoribosyltransferase (NAMPT) inhibitors in Ewing sarcoma CM Heske, MI Davis, JT Baumgart, K Wilson, MV Gormally, L Chen, ... Clinical Cancer Research 23 (23), 7301-7311, 2017 | 51 | 2017 |
| Dual-beam polarization interferometry resolves mechanistic aspects of polyelectrolyte adsorption TJ Lane, WR Fletcher, MV Gormally, MS Johal Langmuir 24 (19), 10633-10636, 2008 | 49 | 2008 |
| Early but not late convalescent plasma is associated with better survival in moderate-to-severe COVID-19 N Briggs, MV Gormally, F Li, SL Browning, MM Treggiari, A Morrison, ... PLoS One 16 (7), e0254453, 2021 | 39 | 2021 |
| Light-mediated in cell downregulation of G-quadruplex-containing genes using a photo-caged ligand P Murat, MV Gormally, D Sanders, M Di Antonio, S Balasubramanian Chemical communications 49 (76), 8453-8455, 2013 | 32 | 2013 |
| Controlling tyrosinase activity on charged polyelectrolyte surfaces: a QCM-D analysis MV Gormally, RK McKibben, MS Johal, CRD Selassie Langmuir 25 (17), 10014-10019, 2009 | 32 | 2009 |
| Small molecule inhibition of FOXM1: How to bring a novel compound into genomic context G Marsico, MV Gormally Genomics Data 3, 19-23, 2015 | 13 | 2015 |
| Registered report: Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukemia JJ Fung, A Kosaka, X Shan, G Danet-Desnoyers, M Gormally, K Owen, ... Elife 4, 529-533, 2015 | 9 | 2015 |
| Enhanced iron availability by protein glycation may explain higher infection rates in diabetics TJ Zwang, MV Gormally, MS Johal, MH Sazinsky Biometals 25, 237-245, 2012 | 9 | 2012 |
| Selective inhibitors of trypanosomal uridylyl transferase RET1 establish druggability of RNA post-transcriptional modifications A Cording, M Gormally, PJ Bond, M Carrington, S Balasubramanian, ... RNA biology 14 (5), 611-619, 2017 | 6 | 2017 |
| a, Lowe C, Matak-Vinković D, et al MV Gormally, TS Dexheimer, G Marsico, D Sanders Suppression of the FOXM1 transcriptional programme via novel small molecule …, 2014 | 5 | 2014 |
| Real-time characterization of polymer film degradation with quartz crystal microbalance with dissipation monitoring M Dixon, M Gormally, M Johal Nanotech Conference & Expo 1, 364-367, 2009 | 3 | 2009 |
| Use of convalescent plasma therapy in severe coronavirus disease 2019: the Yale-New haven health system experience SL Browning, M Gormally, N Briggs, M Li, A Zakko, M Laurent-Rolle, ... Blood 136, 39-40, 2020 | 2 | 2020 |
| Transcription factor as target: Novel small molecule inhibits FOXM1 DNA binding and oncogenic gene products M Gormally, G Marsico, G Rai, C Lowe, C Thomas, D Maloney, S Michael, ... Cancer Research 76 (14_Supplement), 3088-3088, 2016 | 1 | 2016 |
| Identifying novel patient-derived T cell receptors targeting TP53 public neoantigens MV Gormally, SS Chandran, I Etxebarria, C Klebanoff Cancer Research 84 (6_Supplement), 4-4, 2024 | | 2024 |
| Persistence but not antitumor efficacy of CAR-engineered lymphocytes is governed by a FAS/FAS ligand auto-regulatory circuit F Yi, T Cohen, P Zumbo, R Eltilib, H Arkin, M Gormally, CS Hackett, ... Cancer Research 84 (6_Supplement), 40-40, 2024 | | 2024 |
| HLA genotyping and HLA-based clinical trial matching using MSK-IMPACT, a targeted next-generation sequencing assay MF Chen, MV Gormally, AM Noronha, K Panageas, M Reynolds, ... Cancer Research 84 (6_Supplement), 6570-6570, 2024 | | 2024 |
| 903 Phase I trial of tandem intravenous and intraperitoneal delivery of IL-12 armored CAR T cells targeting MUC16 in patients with recurrent high-grade serous ovarian cancer M Gormally, C Klebanoff, R O’Cearbhaill International Journal of Gynecologic Cancer 34 (Suppl 1), 2024 | | 2024 |
TJ LaneGroup Leader, DESYDirección de correo verificada de desy.de
